✦ LIBER ✦

Outcomes of combined modality therapy for patients with stage III or IV mediastinal malignant germ cell tumors

✍ Scribed by Hideki Kuwano, Takehiro Tsuchiya, Tomonori Murayama, Atsushi Sano…

Book ID: 120916781
Publisher: Springer
Year: 2013
Tongue: English
Weight: 204 KB
Volume: 44
Category: Article
ISSN: 1436-2813
DOI: 10.1007/s00595-013-0562-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The value of combined-modality therapy i

The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer

✍ Steven E. Schild; Sumithra J. Mandrekar; Aminah Jatoi; William L. McGinnis; Phil 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to assess the value of combined‐modality therapy in elderly patients by comparing the differences in outcome between patients who received radiotherapy (RT) alone and patients who received RT plus chemotherapy for stage III nonsmall cell l

Post-chemotherapy gross tumor volume is

Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy

✍ Stinchcombe, Thomas E.; Morris, David E.; Moore, Dominic T.; Bechtel, John H.; H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Phase I clinical trial of the anti-EGFR

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

✍ Gwyn Bebb; Colum Smith; Stewart Rorke; William Boland; Leonardo Nicacio; Ryan Su 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 422 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB